CEO SUMMARY: With each passing month, Theranos is looking more like a traditional clinical laboratory company, based on how it is expanding its patient service center network and courier/logistics system into different regions while pursuing managed care contracts with health insurers. Meanwhile, respected laboratory scientists and physicians are using peer-reviewed medical journals to point out that Theranos has yet to publish details about the performance of its diagnostic technology to enable independent validation.
Theranos, Capital Blue Sign Lab Test Agreement
Clinical laboratory company also announces FDA approval of its LDT for herpes simplex 1
- By Joseph Burns
- | From the Volume XXII No. 10 - July 13, 2015 Issue
- Tags: blood testing, blood tests, cap, care contracts, clia, clia lab, clia laboratory, clia registration, clinical biochemistry, clinical chemistry and laboratory medicine, clinical lab, clinical lab test, clinical lab testing, Clinical Laboratory, Diagnostic technology, Diagnostic tests, Elizabeth Holmes, FDA Clearance, hie, impac, lab administrator, lab test, lab testing, lab tests, laboratory company, laboratory director, laboratory medicine, laboratory scientists, laboratory specimen, laboratory specimens, laboratory test, laboratory testing, laboratory testing services, laboratory tests, ldt, managed care, managed care contract, managed care contracts, medical lab, Medical laboratory, medical laboratory test, medical laboratory tests, pathologists, quality assurance, quality assurance program, quality assurance programs, Theranos
